[go: up one dir, main page]

BR9908088A - Formulação farmacêutica de um composto de didemnin - Google Patents

Formulação farmacêutica de um composto de didemnin

Info

Publication number
BR9908088A
BR9908088A BR9908088-5A BR9908088A BR9908088A BR 9908088 A BR9908088 A BR 9908088A BR 9908088 A BR9908088 A BR 9908088A BR 9908088 A BR9908088 A BR 9908088A
Authority
BR
Brazil
Prior art keywords
didemnin
pharmaceutical formulation
compound
didemnin compound
lyophilized
Prior art date
Application number
BR9908088-5A
Other languages
English (en)
Other versions
BR9908088B1 (pt
BRPI9908088C1 (pt
BRPI9908088B8 (pt
Inventor
Jacob Hendrik Beijnen
Bastiaan Nuyen
Roland Elizabeth Cornel Henrar
Andres Gomez
Jose Jimeno
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10827213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9908088(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of BR9908088A publication Critical patent/BR9908088A/pt
Publication of BR9908088B1 publication Critical patent/BR9908088B1/pt
Publication of BRPI9908088B8 publication Critical patent/BRPI9908088B8/pt
Publication of BRPI9908088C1 publication Critical patent/BRPI9908088C1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Patente de Invenção: <B>"FORMULAçãO FARMACêUTICA DE UM COMPOSTO DE DIDEMNIN"<D>. Uma composição farmacêutica estável de um composto de didemnin, compreende em primeiro lugar uma preparação de didemnin liofilizada incluindo material solúvel em água e em segundo lugar uma solução de reconstituição de solventes mistos.
BRPI9908088A 1998-02-18 1999-02-18 composição farmacêutica de aplidina e seu método de preparação. BRPI9908088C1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9803448.1A GB9803448D0 (en) 1998-02-18 1998-02-18 Pharmaceutical formulation
PCT/GB1999/000511 WO1999042125A1 (en) 1998-02-18 1999-02-18 Pharmaceutical formulation of a didemnin compound

Publications (4)

Publication Number Publication Date
BR9908088A true BR9908088A (pt) 2000-10-31
BR9908088B1 BR9908088B1 (pt) 2013-05-21
BRPI9908088B8 BRPI9908088B8 (pt) 2017-03-07
BRPI9908088C1 BRPI9908088C1 (pt) 2021-05-25

Family

ID=10827213

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9908088A BRPI9908088C1 (pt) 1998-02-18 1999-02-18 composição farmacêutica de aplidina e seu método de preparação.

Country Status (17)

Country Link
US (1) US8420130B1 (pt)
EP (1) EP1054686B1 (pt)
JP (2) JP4536255B2 (pt)
KR (1) KR100595597B1 (pt)
CN (1) CN1170586C (pt)
AT (1) ATE217532T1 (pt)
AU (1) AU754073B2 (pt)
BR (1) BRPI9908088C1 (pt)
CA (1) CA2321116C (pt)
DE (1) DE69901487T2 (pt)
DK (1) DK1054686T3 (pt)
ES (1) ES2175940T3 (pt)
GB (1) GB9803448D0 (pt)
HK (1) HK1032538A1 (pt)
IL (1) IL137911A (pt)
PT (1) PT1054686E (pt)
WO (1) WO1999042125A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
DE10008128A1 (de) * 2000-02-22 2001-08-23 Bayer Ag Endoparasitizide Mittel
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
US7507766B2 (en) 2000-10-12 2009-03-24 Pharma Mar, S.A. Treatment of cancers
AU2002210749B2 (en) * 2000-10-31 2006-12-21 Pharma Mar, S.A. Kahalalide F formulation
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
RU2341283C2 (ru) * 2003-03-12 2008-12-20 Фарма Мар, С.А. Усовершенствованное лечение опухолей
RU2335294C2 (ru) * 2003-03-12 2008-10-10 Дана-Фарбер Кэнсер Инститьют, Инк. Аплидин для лечения множественной миеломы
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CN100335495C (zh) * 2006-01-23 2007-09-05 南方医科大学 一种海鞘多肽及其制备方法
EP2029155B1 (en) 2006-02-28 2016-04-13 Pharma Mar S.A. Improved treatment of multiple myeloma
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
US10286037B2 (en) * 2011-02-09 2019-05-14 Glaxosmithkline Llc Methods of producing lyophilized polypeptide composition formulations comprising volatile additives
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
US20230158104A1 (en) 2020-03-02 2023-05-25 Pharma Mar, S.A. Compounds for use in autoimmune conditions
JP2023517295A (ja) 2020-03-02 2023-04-25 ファルマ、マール、ソシエダード、アノニマ コロナウイルス感染の処置に使用する化合物
EP4114434A1 (en) 2020-03-02 2023-01-11 Pharma Mar, S.A. Pld for use in combination in the treatment of coronavirus
PE20230606A1 (es) 2020-03-02 2023-04-10 Pharma Mar Sa Compuestos para su uso en infecciones viricas
CN114085272B (zh) * 2022-01-10 2022-06-10 中山大学 一种isaridin类环酯肽衍生物及其制备方法和应用
WO2024165764A1 (en) 2023-02-10 2024-08-15 Pharma Mar, S.A. Plitidepsin for use in the treatment of non-integrated dna viral infections

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342744A (en) * 1979-07-19 1982-08-03 Lever Brothers Company Hair treatment products
DE3161556D1 (en) 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
JPS5781413A (en) * 1980-09-12 1982-05-21 Univ Illinois Didemnin antibiotic
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid preparations of gamma interferon
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
ATE220894T1 (de) * 1993-12-29 2002-08-15 Matrix Pharma Zusammensetzung für lokale freigabe von zytostatika
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
US6365597B1 (en) * 1996-02-14 2002-04-02 Aventis Pharmaceuticals Inc. 4-aza steroids
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
WO1997044026A1 (en) 1996-05-22 1997-11-27 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
EP0918693B1 (en) 1996-07-03 2001-11-07 C G Paxton Limited Containers
WO1998017302A1 (en) 1996-10-24 1998-04-30 The Board Of Trustees Of The University Of Illinois Total synthesis of the amino hip analogue of didemnin a
AU731757B2 (en) 1996-10-24 2001-04-05 Board Of Trustees Of The University Of Illinois, The Semi-synthetic studies toward didemnin analogues
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
ATE421329T1 (de) * 1997-05-07 2009-02-15 Pharma Mar Sa Verwendung von aplidine zur behandlung von kardiovaskulären erkrankungen
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
EP1100589B1 (en) 1998-07-30 2005-01-19 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Use of propionyl l-carnitine and acetyl l-carnitine in the preparation of medicaments with anticancer activity
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
AU781897B2 (en) 1999-05-25 2005-06-23 Point Therapeutics, Inc. Anti-tumor comprising boroproline compounds
SK287762B6 (sk) 1999-11-15 2011-09-05 Pharma Mar, S. A. Použitie aplidínu na prípravu farmaceutického prostriedku na liečenie rakoviny
BR0109958A (pt) 2000-04-07 2003-05-27 Univ Pennsylvania Análogos de didemnina e tamandarina e métodos de preparação e uso deles
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
JP2004528008A (ja) 2000-10-05 2004-09-16 イミュネックス・コーポレーション ネクチンポリペプチド、ポリヌクレオチド、該ポリペプチドおよびポリヌクレオチドを作成し、そして使用する方法
HUP0302293A3 (en) 2000-10-12 2006-04-28 Pharma Mar Sa Treatment of cancers by aplidine in conjunction with a myoprotector
WO2002032374A2 (en) 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
EP1435991B1 (en) 2001-10-19 2008-10-15 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
RU2341283C2 (ru) 2003-03-12 2008-12-20 Фарма Мар, С.А. Усовершенствованное лечение опухолей

Also Published As

Publication number Publication date
HK1032538A1 (en) 2001-07-27
BR9908088B1 (pt) 2013-05-21
CN1170586C (zh) 2004-10-13
GB9803448D0 (en) 1998-04-15
AU754073B2 (en) 2002-11-07
DE69901487T2 (de) 2002-12-19
PT1054686E (pt) 2002-09-30
CA2321116A1 (en) 1999-08-26
AU2538999A (en) 1999-09-06
ATE217532T1 (de) 2002-06-15
DE69901487D1 (de) 2002-06-20
BRPI9908088C1 (pt) 2021-05-25
ES2175940T3 (es) 2002-11-16
WO1999042125A1 (en) 1999-08-26
CA2321116C (en) 2009-10-06
IL137911A (en) 2006-04-10
JP2002503704A (ja) 2002-02-05
IL137911A0 (en) 2001-10-31
CN1330551A (zh) 2002-01-09
DK1054686T3 (da) 2002-06-17
JP2010163443A (ja) 2010-07-29
EP1054686B1 (en) 2002-05-15
EP1054686A1 (en) 2000-11-29
KR20010040993A (ko) 2001-05-15
US8420130B1 (en) 2013-04-16
BRPI9908088B8 (pt) 2017-03-07
JP4536255B2 (ja) 2010-09-01
KR100595597B1 (ko) 2006-07-03

Similar Documents

Publication Publication Date Title
PT1054686E (pt) Formulacao farmaceutica de um composto de didemnina
ATE383169T1 (de) Komponente und zusammensetzungen zur verabreichung von wirkstoffen
FI971776A (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
TR200100366T2 (tr) Aktif madde dağıtmaya mahsus bileşikler ve bileşimler.
DE69528057D1 (de) Tocopherolzusammensetzungen zur Abgabe von biologisch aktiven Substanzen
MY118835A (en) Sustained release compositions and the process for their preparation
EP1100522A4 (en) ADMINISTRATION OF ACTIVE AGENTS OVER THE LUNG
TR200002299T2 (tr) Epotilon kompozisyonları.
ATE554750T1 (de) Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
YU23302A (sh) Farmaceutski preparati fibrinolitičkog agensa
DE60024414T2 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
AU1307399A (en) Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same
CA2335551A1 (en) Thyroid hormone analogues and methods for their preparation
HRP20030050B1 (en) Sustained-release preparations of quinolone antibiotics and method for preparation thereof
IL143578A0 (en) Lipidized conjugates containing an amino group-containing biologically active substance and pharmaceutical compositions containing the same
BG105303A (en) Pharmaceutical compositions comprising ibuprofen and domperidone
AR019499A1 (es) FORMULACIONES ANTIPARÁSITOS Y USO EN LA FABRICACIoN DE MEDICAMENTOS
GB9718415D0 (en) Formulation

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO DE ARQUIVAMENTO DO PEDIDO POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/05/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/02/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 18/02/2019